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Abstract
AIM: To evaluate pain control in chronic pancreatitis 
patients who underwent total pancreatectomy with 
islet cell transplantation or intrathecal narcotic pump 
infusion.
METHODS: We recognized 13 patients who underwent 
intrathecal narcotic pump (ITNP) infusion and 57 
patients who underwent total pancreatectomy with 
autologous islet cell transplantation (TP + ICT) for 
chronic pancreatitis (CP) pain control between 1998 and 
2008 at Indiana University Hospital. All patients had 
already failed multiple other modalities for pain control 
and the decision to proceed with either intervention was 
made at the discretion of the patients and their treating 
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physicians. All patients were evaluated retrospectively 
using a questionnaire inquiring about their pain control 
(using a 0-10 pain scale), daily narcotic dose usage, 
and hospital admission days for pain control before 
each intervention and during their last follow-up. 
RESULTS: All 13 ITNP patients and 30 available TP 
+ ICT patients were evaluated. The mean age was 
approximately 40 years in both groups. The median 
duration of pain before intervention was 6 years and 7 
years in the ITNP and TP + ICT groups, respectively. 
The median pain score dropped from 8 to 2.5 (on a 
scale of 0-10) in both groups on their last follow up. 
The median daily dose of narcotics also decreased 
from 393 mg equivalent of morphine sulfate to 8 mg 
in the ITNP group and from 300 mg to 40 mg in the 
TP + ICT group. No patient had diabetes mellitus (DM) 
before either procedure whereas 85% of those who 
underwent pancreatectomy were insulin dependent on 
their last evaluation despite ICT. 
CONCLUSION: ITNP and TP + ICT are comparable 
for pain control in patients with CP however with high 
incidence of DM among those who underwent TP + 
ICT. Prospective comparative studies and longer follow 
up are needed to better define treatment outcomes. 
Key words: Chronic pancreatitis; Intractable pain; Total 
pancreatectomy; Islet cell transplantation; Intrathecal 
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Core tip: Total pancreatectomy (TP) is the last resort 
offered to chronic pancreatitis (CP) patients with 
intractable pain when other interventions have failed. 
We wanted to compare pain control and rate of 
insulin-dependent diabetes in CP patients after TP and 
autologous islet cell transplantation (ICT) or intrathecal 
narcotic pump infusion, which is a relatively new and 
less invasive technique used for chronic analgesia in 
multiple other clinical settings. We found that pain 
control was similar between the two interventions 
after a median follow-up of 3 years yet the rate of 
insulin-dependent diabetes was still high in the surgical 
resection group despite the ICT. 
Mokadem M, Noureddine L, Howard T, McHenry L, Sherman S, 
Fogel EL, Watkins JL, Lehman GA. Total pancreatectomy with 
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INTRODUCTION
Abdominal pain remains the most common and 
difficult to treat complaint for patients with chronic 
pancreatitis as it can often be severe and debilitating. 
There is still lack of full understanding of the exact 
mechanism of pain in chronic pancreatitis (CP) and 
factors contributing to it are only partially defined[1-3]. 
The general goals of treatment include pain relief in 
addition to prevention and management of disease 
related complications such as pseudocysts, strictures, 
malabsorption (exocrine failure) and diabetes mellitus 
(endocrine failure). Opiates, however, remain the most 
frequently used analgesics in the background of all 
other treatment options. It is the generally acceptable 
approach to start with the least invasive intervention 
first, such as alcohol and smoking abstinence, and 
then advance in a stepwise manner as the method 
fails[4-6]. Total pancreatectomy (TP) is considered the 
final resort offering additional pain control to most 
patients with remaining intractable pain at the expense 
of developing insulin dependent diabetes. The addition 
of autologous islet cell transplantation (ICT) to TP has 
been shown to have variable success in prevention 
of insulin dependence from zero up to a maximum of 
40% based on the performing center and the duration 
of follow up[7-9]. Neuroaxial blockage modalities such 
as spinal cord stimulation or intrathecal analgesia are 
among the newer modalities that may have a role in 
CP. Experience in this field, however, has been limited 
to case reports[10-12]. Among these, the intrathecal 
narcotic pump infusion (ITNP) is the most studied 
modality for control of intractable pain in cancer as 
well as non-cancer patients but with variable level of 
success[13-16]. The ITNP consists of a channeled catheter 
intrathecally (into the subarachnoidal space) that is 
connected to a small battery-powered programmable 
pump which is placed in the subcutaneous tissue of the 
abdominal wall. In our institution, we used a Medtronic 
Synchro MedII pump that possesses a 40 ml drug 
reservoir that is filled via a transcutaneous route under 
sterile conditions every 1-6 mo[17]. The literature has 
been scarce regarding its role and efficacy in patients 
with CP. In 2009, Kongkam et al[17] published a pilot 
study from the same center suggesting a promising 
role of ITNP in these patients.
MATERIALS AND METHODS
Using hospital electronic records and the endoscopic 
retrograde cholangiopancreatography (ERCP) database 
at Indiana University Medical Center from 1998 to 
2008, we identified 13 patients who underwent ITNP 
infusion and 57 patients who underwent TP + ICT 
for CP and control of pain. The goal was to assess 
pain control in a cohort of surgical patients that is at 
least two fold the previously reported cohort of ITNP 
patients. All patients were managed at the discretion 
of their gastroenterology treating physicians at Indiana 
University and different approaches were selected 
based on clinical judgment and patient preferences. 
When patients’ final decision was to undergo ITNP, the 
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procedure was arranged and performed at Indiana 
University Hospital. On the other hand, when patients 
decided to proceed with TP + ICT, the surgery was 
arranged to be performed in one of three different 
surgical centers that offer this procedure- including 
Indiana University Hospital- based on patients’ pre-
ferences and proximity to their household. Patients 
with persistent evidence of increased duct pressure 
were offered surgical or endoscopic decompression 
procedures - as appropriate - before being considered 
for total resection. All patients available for follow up 
answered a phone call-based questionnaire inquiring 
about their pain level, their daily narcotic use and the 
number and duration of hospital admissions for pain 
control. 
The phone call inquiry about pain control is part of 
the standard care provided by the gastroenterology 
group at Indiana University. Verbal informed consent 
was obtained from all patients before proceeding with 
the questions. The study design abides by the ethical 
guidelines of the “World Medical Association Declaration 
of Helsinki - Ethical Principles for Medical Research 
Involving Human Subjects”. Pain was assessed sub-
jectively using a zero to ten scales (0 being no pain and 
10 being maximum pain) before each procedure and on 
the last follow up available. All the daily narcotics used 
before and after the procedures were recorded and 
converted to milligram (mg) equivalent of oral morphine 
sulfate using a pharmacologic online converter http://
www.globalrph.com/narcotic.cgi. 
The number of in-hospital days per year for pain 
control was defined as the number of in-hospital 
admissions multiplied by the average duration of each 
admission (in days) divided by the total number of 
pain-years. This was recorded in each group before 
and after each intervention. Finally, the diabetes 
mellitus status, the average units of insulin used per 
day and the last HbA1C (glycosylated hemoglobin) 
were also recorded among the surgical group candi-
dates on their last follow up.
Statistical analysis
All data are presented as median or mean ± standard 
deviation. Only P-values that are less than 0.05 
were considered statistically significant. Experiments 
comparing two means were analyzed using Student’s 
t-test with Welch’s correction if appropriate. 
RESULTS
The thirty patients who answered the phone call 
questionnaire constituted the surgery study group 
while no data was available from the remaining 27 
surgical candidates. All 13 ITNP patients (5 male, 8 
female) and the 30 TP + ICT patients (6 male, 24 
female) contacted were Caucasians with a mean age of 
40.6 years (± 9.6) and 39.9 years (± 14) respectively. 
The median duration of pain was 6 years (range 2-22) 
in the ITNP group and 7 years (range 1-21) in the TP + 
ICT group before each procedure. The median duration 
of follow up was 3 years in both groups with a range of 
0.5 to 9 years in the ITNP group and 0.5 to 10 years in 
the TP + ICT group. The most common etiology of CP 
was idiopathic in the TP + ICT group (approximately 
63%) followed by pancreatic divisum (approximately 
17%), while it was pancreatic divisum (46%) followed 
by idiopathic in the ITNP group (approximately 23%). 
Alcohol constituted 15% of the ITNP group and 
approximately 7% of the surgery group (Table 1). 
One ITNP patient developed serious meningitis 
requiring permanent removal of the catheter and 
pump and was excluded from the study. Three surgical 
patients were reported dead by their families upon 
contact, leaving 12 ITNP and 27 TP + ICT patients 
for retrospective comparison. All patients underwent 
multiple interventions for attempted pain control before 
either procedures such as ERCP with sphincterotomy 
(100% in both groups), celiac plexus neurolysis (46% 
of ITNP and 50% of TP + ICT), enteral tube feeding for 
bowel rest (61% of ITNP and approximately 33% of TP 
+ ICT), and surgery (approximately 61% in ITNP and 
approximately 33% in TP + ICT). 
The most common surgical procedure performed 
was denervation (bilateral splanchnicectomy) in the 
ITNP group and decompression (Puestow procedure) 
in the TP + ICT group (Table 2). 
Pain control
The pain score dropped from a mean of 8.1 (± 1.4) 
and a median of 8 before the ITNP to a mean of 2.5 
(± 2.2) and a median of 2.5 on the last follow up 
(Figure 1A). Similarly, the pain score dropped from 
a mean of 8.0 (± 1.7) and a median of 8 before the 
TP+ICT to a mean of 2.7 (± 2.9) and a median of 2.5 
on the last follow up (Figure 1B). No ITNP patients 
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Table 1  Etiology of chronic pancreatitis among patients who underwent intrathecal narcotic pump or total pancreatectomy + islet 
cell transplantation  n  (%)
Idiopathic Pancreatic divisum Alcohol induced Gallstone induced Auto-immune
ITNP group   6/13 (46.1) 3/13 (23.1) 1/13 (7.7)   2/13 (15.4)    1/13 (7.7)
TP + ICT group 19/30 (63.3) 5/30 (16.7)   4/30 (13.3) 2/30 (6.7) 0/30 (0)
ITNP: Intrathecal narcotic pump; TP: Total pancreatectomy; ICT: Islet cell transplantation. 
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(± 234) before surgery to a median of 40 mg and a 
mean of 104 mg (± 170) on their last clinic follow up, 
respectively (P < 0.05) (Figure 2B). 
Two ITNP patients had increase in their oral daily 
narcotic requirements, one patient had very minimal 
decrease in his dose and six were narcotic free on 
their last follow up. The duration of follow up for these 
patients ranged from 0.5 to 7 years with a median of 
1.5 years. The average dose of intrathecal morphine 
was 7.5 mg (2-10 mg). Three TP + ICT had increase 
in their daily narcotic requirements and 9 patients 
were narcotic free on their last follow up. The duration 
of follow up ranged from 1 to 10 years with a median 
of 4 years. These same 9 patients also reported zero 
pain (Figure 2A and B).
reported increase in their pain score and 3 out of 12 
were still pain free on their last follow up (duration of 
last follow up was 0.5, 5, and 9 years respectively). 
Two TP + ICT patients reported worsening of their pain 
after surgery and one reported no change. 12 surgical 
patients were still pain free on their last follow up 
with a median duration of 4 years. The daily narcotics 
usage among ITNP patients decreased from a median 
of 393 mg equivalent of morphine sulfate and a mean 
of 553 mg (± 448) before intervention to a median 
of 8 mg and a mean of 158 mg (± 349) on their last 
clinic follow up, respectively (P < 0.05) (Figure 2A). 
likewise, TP + ICT patients experienced a drop in 
their daily narcotics usage from a median of 300 mg 
equivalent of morphine sulfate and a mean of 316 mg 
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Table 2  Multiple interventions performed in patients with chronic pancreatitis for pain control before undergoing intrathecal 
narcotic pump or total pancreatectomy + islet cell transplantation  n  (%)
ERCP with sphincterotomy Celiac Block 
(EUS or CT)
Jejunal or Gastro-Jejunal tube 
insertion
Surgeries 
(denervation or decompression)
ITNP group 13/13 (100)   6/13 (46)   8/13 (61)   8/13 (61)
TP + ICT group 30/30 (100) 15/30 (50) 10/30 (33) 10/30 (33)
ITNP: Intrathecal narcotic pump; TP: Total pancreatectomy; ICT: Islet cell transplantation; EUS: Endoscopic ultrasonography; CT: Computed tomography; 
ERCP: Endoscopic retrograde cholangiopancreatography. 
Figure 1  The average daily pain scores (on a scale of 0-10) in chronic 
pancreatitis patients before undergoing intrathecal narcotic pump 
infusion (A) and total pancreatectomy + islet cell transplantation (B) at the 
last follow-up.
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Figure 2  The average daily dose of narcotics (in mg equivalents of oral 
morphine sulfate) in chronic pancreatitis patients before undergoing 
intrathecal narcotic pump infusion (A) and total pancreatectomy + islet 
cell transplantation (B) at the last follow-up.
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Hospital admissions
The number of in-hospital days per year (d/year) for 
pain control decreased from a mean of 22 d/year (± 
34) and a median of 15 d/year before ITNP to a mean 
of 1 d/year (± 1.5) and a median of zero thereafter. 
Only one patient reported increase in his hospital 
admission days per year for pain control and 7 patients 
(64%) have not been admitted to the hospital for 
pain control as of their last follows up. likewise, the 
number of hospital days dropped from a mean of 29 
d/year (± 30) and a median of 15 d/year before total 
pancreatectomy to a mean of 8 d/year (± 2) and a 
median of zero on the last follow up. Two patients 
reported increase in their hospital admission days per 
year and 15 patients (55%) have not been admitted 
to the hospital for pain control as of their last follow up 
(Figure 3A and B).
Complications
No patient had diabetes mellitus before either 
intervention in both groups. Only 4 out of the 27 
surgical patients (approximately 15%) were insulin free 
on their last follow up despite the autologous islet cell 
transplantation. The average insulin dose per day was 
25 units among the new diabetics with a median of 21 
units (range = 4-54 units). The last HbA1c reported by 
the TP + ICT patients had an average of 7.35% and 
a median of 6.6% (Table 3). There were 3 deaths in 
the TP + ICT group (10% mortality rate), 2 were due 
to sepsis occurring at 3 wk and 1 mo after surgery as 
reported by family. However, no further information 
was available for the third death case. One TP + ICT 
patient had abscess formation in the abdomen post-
surgery requiring drainage. No other major surgical 
complications were reported by patients during the 
questionnaire; however, no surgical records were 
available for patients operated on at other institutions. 
No death to date occurred in our series among the 
ITNP group. Two out of the 13 patients who underwent 
the ITNP infusion had bacterial meningitis. One of 
them was serious enough to necessitate catheter 
and pump removal and was excluded from the study. 
One patient had CSF leak (7.7%) that was surgically 
repaired with no further reported complications. 
DISCUSSION
Here we report two relatively similar series of patients 
with intractable pain due to chronic pancreatitis who 
underwent either an intrathecal narcotic pump infusion 
or total pancreatectomy with islet cell transplantation 
as a terminal procedure for pain control after failure 
of multiple other modalities. We considered two ITNP 
patients to have failed treatment because of higher 
narcotic use and increased hospital admission days 
upon their last follow up despite having lower pain 
scores. 
likewise, three TP + ICT patients can also be 
reported as failure due to worsening pain, higher 
narcotic use and increase in hospital admissions 
in 2 of them, and only higher narcotic use in the 
remaining one. Therefore, in our case series, success 
rate was observed as 77% (10/13) among the 
ITNP group and 80% (24/30) among the TP + ICT 
group for pain control. Most of the published case 
series reported a post-operative morbidity range 
(e.g. infections, anastomosis leak, etc.) between 
25 and 68% but major complications constituted 
approximately 14%-18% based on their reporting[7,9,18]. 
Several series from single centers reported a peri-
operative mortality rate (usually defined as mortality 
within 2 wk of surgery) of 0% to 3.5% from total 
pancreatectomy[7-9,18-20]. Our multi-center based data 
was incomplete as we were unable to record the 
morbidity and mortality among all 57 surgical patients. 
However, the thirty-day mortality, which may not 
reflect the exact peri-operative mortality, is found to 
be at best 3.5% (3 out of 57) and at worst 10% (3 out 
of 30). The rate of serious complications (like bacterial 
meningitis, CSF leak and pump or catheter migration) 
from intrathecal analgesia is not clear in the literature 
but reports vary from 0% to 20% depending on the 
center, the population studied, and duration of follow 
up[14-16]. Anderson et al[16] and Kumar et al[14] reported 
a success rate of 50% and 75% respectively using 
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Figure 3  Number of hospital admission days per year for pain control 
among chronic pancreatitis patients before undergoing intrathecal 
narcotic pump infusion (A) and total pancreatectomy + islet cell 
transplantation (B) at the last follow-up.
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intrathecal morphine in patients with chronic non-
malignant pain after an average duration of follow up 
of approximately 2 years. This, however, drops to 30% 
and 44% respectively when success rate is defined as 
more than 50% reduction in visual pain scores[14,16]. 
It is important to note that all our successful ITNP 
patients (10 out of 13) had more than 50% reduction 
in their pain scores with an average intrathecal 
morphine dose of 7.5 mg/d (range 2.5-10 mg/d). 
Our results from TP + ICT have been consistent 
with several previous series reporting successful 
pain control and narcotic independence in 70%-80% 
of subjects within 6-12 mo after surgery[8,9,18,19]. 
Garcea et al[20] reported in a a series of 85 pts who 
underwent TP + ICT for CP that narcotic-free patients 
dropped from 90% after surgery to 40% at 1 year 
and ultimately to l6% at 5 years. On the other hand, 
Riediger et al[21] reported 87% improvement in 
pain control of 224 patients as far as 10 years after 
pancreatic head resection. However, 72% of these 
patients were back on narcotic medications despite 
using lower doses. Therefore, the success rate of pain 
control after pancreatectomy seems to depend largely 
on the definition of “success”[21]. Nonetheless, the 
most effective and most durable pancreatic surgeries 
performed for pain control in chronic pancreatitis 
seem to involve resection of the head of pancreas 
when compared with denervation or decompression 
procedures[18-21].
Our series had a 3 years median duration of 
follow up raising the question about the durability of 
the reported rate of 80%. The complete success of 
the autologous islet cell graft with resulting insulin 
independence has variably been reported to range 
from zero up to 40% within duration of follow up 
between 6 and 24 mo[8,9,18,19]. Garcea et al[20] again 
showed in his series that insulin independence 
dropped from 14.1% post engraftment to 5.9% after 
a median follow up duration of 8 years. However, there 
still might be a role for ICT in diabetes management 
after TP since there is evidence of partial graft 
function in patients with insulin-dependent diabetes 
after pancreatectomy but with relatively low insulin 
requirements. Therefore, ICT may probably add 
some protection against hypoglycemia events and 
long-term diabetes complications. However, this 
need to be evaluated independently[20,22]. Female 
gender, lower body weight and higher number of 
islet cells transplanted have been suggested to be 
positive predictive factors of graft survival[8,18,19]. Our 
data show a complete preservation of islet cells graft 
function in 15% of pts after a median follow up of 3 
years (range 0.5-10 years) and an acceptable glucose 
control (average HbA1c 7.35%) with moderate insulin 
requirements (average 25 units/d) compared to 
patients with type 1 diabetes. Further follow-up of 
these patients is very important in order to assess 
for any further change in the islet cell graft viability 
and insulin requirements as in Garcea’s report[20]. The 
incidence of diabetes mellitus complications awaits 
further follow up. Positive outcomes were very similar 
among both treatment modalities (Table 4) but major 
limitations still exist in our series. 
First, the study is retrospective as it will be difficult 
to prospectively design a large population study in 
patients with CP, especially when it involves very 
extensive surgery such as total pancreatectomy with 
islet cell transplantation a procedure performed in only 
few selected centers in the United States. Second, 
the ITNP and surgical interventions were performed 
in different institutions which make comparison more 
difficult given the variability in technical performance. 
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Table 3  Status of insulin-dependent diabetes among all surgical patients before and after total pancreatectomy with islet cell 
transplantation
Number of patients with insulin independence Average dose of insulin/day (units) Average HbA1c
Before TP + ICT 30/30 (100%) 0 N/A
After TP + ICT 4/27 (approximately 15%) 25 7.35%
ITNP: Intrathecal narcotic pump; TP: Total pancreatectomy; ICT: Islet cell transplantation. 
Table 4  Summary of outcomes among patients with intrathecal narcotic pump and those with total pancreatectomy and islet cell 
transplantation
ITNP TP + ICT Comparison
Reversibility of the procedure Yes No Different
Success rate for pain control 77% 80% Similar
Residual narcotic dose usage (mg equivalent of oral morphine sulfate) Mean = 158 mg/d Mean = 104 mg/d Similar
Median = 8 mg/d Median = 40 mg/d
Percentage of patients with poor pain control 16.7% 11.1% Similar
Percentage of patients with new insulin dependent diabetes 0% Approximately 85% Different
Procedure related death 0% 10% Different
ITNP: Intrathecal narcotic pump; TP: Total pancreatectomy; ICT: Islet cell transplantation.
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This discrepancy was due to the fact that ITNP was 
offered at Indiana University Hospital by the treating 
gastroenterologist there as a one day procedure like 
all other interventions provided. However, when the 
ultimate decision was to go for TP + ICT and since 
some patients came from out-of-state, the surgical 
center was chosen based on proximity to patients’ 
homes and social support. Third, not all surgical 
patients were assessed due to the fact that many 
surgeries were performed in multiple institutions and 
medical records were not available to us for review. 
In addition, three years median duration of follow up 
is still considered modest for CP. larger comparative 
series with longer duration of follow up are needed 
to better characterize the optimal management of 
intractable pain in patients with chronic pancreatitis.
In conclusion, our case series compared two 
advanced interventions offered to chronic pancreatitis 
patients who failed several conventional therapies 
and continued to have high reported levels of daily 
pain coupled with consumption of large dosages of 
narcotics. Total pancreatectomy is a morbid surgery 
associated with well-known short and long term 
peri-operative risks with insulin-dependent diabetes 
being one of its major sequelae. Based on our data, 
the addition of islet cell transplantation to total 
pancreatectomy may offer a protective effect from 
insulin dependence at least for few years. This surgical 
procedure is not readily accessible to many patients 
within the United States or around the world. 
On the other hand, intrathecal narcotic pump 
infusion is a relatively newer, less invasive therapeutic 
technique that delivers significantly lower doses of 
narcotics to the spinal fluid, therefore minimizing major 
systemic side effects of narcotics such as tolerance 
and constipation. There is very limited data of its long 
term efficacy and complications in chronic pancrea-
titis patients but observations can be extrapolated 
from reported patients with central nervous system 
disorders. Based on our data, ITNP seems to have a 
promising role as it showed comparable effect to total 
pancreatectomy on pain control with the additional 
benefit of preserving glucose and insulin metabolism. 
Future prospective studies in selected patients with 
chronic pancreatitis will better define its future role in 
pain management. 
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Background
Chronic pancreatitis (CP) patients who still have intractable abdominal pain 
despite undergoing several endoscopic and surgical interventions for analgesia 
are left with very few options short of having a complete resection of their 
pancreas. Total pancreatectomy is associated with adverse effect of insulin-
dependent diabetes which may be reversed or delayed by performing islet 
cell transplantation via infusion of isolated islet cells into the portal system. 
However, this surgery carries a significant risk of morbidity and mortality and is 
usually reserved as the last resort for pain control in chronic pancreatitis.
Research frontiers
Intrathecal narcotic pump infusion is a minimally invasive procedure aimed at 
delivering very low dose of narcotics to the spinal fluid through a small catheter 
for the purpose of analgesia with minimal narcotic’s side effects. This pump 
is currently used to manage severe pain in patients with refractory abdominal 
malignancies and in those with central nervous system injury and secondary 
spasms. 
Innovations and breakthroughs
The authors examine - in a rare comparison - multiple markers of pain control 
in chronic pancreatitis patients who underwent either total pancreatectomy with 
islet cell transplantation or the less invasive yet relatively new procedure of 
intrathecal narcotic pump infusion.
Applications
The intrathecal narcotic pump (ITNP) infusion seems to have similar pain 
control to total pancreatectomy with islet cell transplantation (TP + ICT) with 
significant lower incidence of insulin-dependent diabetes. This modality may 
be considered as an option in chronic pancreatitis patients with intractable pain 
who refuse or do not qualify for total pancreatectomy.
Peer-review
This is a retrospective study of TP + ICT and ITNP for the control of intractable 
pain in CP. The aim is to evaluate pain control in patients with CP from a 
single center. Small series, but exceptionally well conducted, analyzed, and 
written. This is an important message that there may be a viable non-surgical 
alternative to TP and ICT for intractable pain in CP.
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